AVIYA helps Private Equity firms to greatly minimize risk and improve investment decisions by providing critical scientific, medical and operational due diligence. AVIYA provides key insight into the competitive landscape of specific therapeutic areas, to develop an accurate view of a product’s real potential.

Venture Capital firms have played a critical role in the biotechnology industry from its very beginnings. The industry has grown up and today’s biotech and biopharmaceutical companies have adjusted their approach to developing new products. Still the fact remains that drug discovery is high-risk proposition; only 2 of 10 new drugs to enter clinical trials ever makes it to market.

The outlook is even more bleak when one looks at the chances of a preclinical compound making it through to market. Despite the risk however, some venture firms and other private equity investors are having great success with their biotechnology portfolios.

The success of these firms is driven by a deep understanding of the science and clinical landscape of the sector, and the therapeutic areas in which they are investing.

An accurate assessment of the scientific merits, clinical relevance and commercial viability of a biopharmaceutical or device forms the basis of an enlightened funding decision.